Overview

Study of Urelumab in Subjects With Advanced and/or Metastatic Malignant Tumors

Status:
Completed
Trial end date:
2016-11-11
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and tolerability of BMS-663513 in subjects with advanced and/or metastatic malignant tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Bristol-Myers Squibb
Collaborator:
Ono Pharmaceutical Co. Ltd
Treatments:
Nivolumab